Armoring India Against Infectious Disease

Building a self-reliant future through first-in-class drug innovation and advanced biosafety research in Andhra Pradesh.

Our Mission

To restore immunity and reverse disease by developing deep-tech breakthroughs for a healthier India.

Aligned with India’s Future

Atmanirbhar Bharat Health (Self-Reliance Health)

Moving beyond generics to indigenous, first-in-class drugs developed by a world-class R&D team completing research locally in India.

Viksit Bharat 2047

Contributing to the vision of a "Developed India" by building a robust biotechnology ecosystem.

Read Our Press Release

The Claromer® Platform

Immune System Mimic

Claromers are small molecules designed to mimic the human body’s innate immune defense.

Any Pathogen

Claromer molecules target a broad spectrum of viruses, bacteria and fungi simultaneously.

No Bacterial Resistance

In lab tests, bacteria do not develop resistance to this technology.

Shelf-Stable

These molecules require no refrigeration, making them ideal for delivery in rural areas and villages.

Our Facilities

Andhra Pradesh Centre for
Advanced Research on Livestock (APCARL)

World-Class Infrastructure

Our partnership with the Andhra Pradesh Centre for Advanced Research on Livestock delivers advanced R&D laboratories and underground BSL-4 biocontainment facilities.

A Hub for Innovation

The 671-acre, self-contained campus in Pulivendula serves as our core site for drug research and development.

Regional Strength

Strategically located near the Bengaluru biotech corridor, APCARL delivers a talented pool of scientists and engineers.

Neonatal sepsis is just the beginning.

Our stable, small molecules are the solution for India’s anti-microbial resistance crisis.

  • The 2nd leading cause of infant mortality in India (700,000 annual cases resulting in 200,000 infant deaths - 3 million globally).

  • 134 million Indians suffer from infectious sinusitis; 6.7 million cases are antibiotic-resistant.

  • High mortality rates in diabetic and immunocompromised populations.

  • Contamination risks can lead to batch failure and escalate costs.